TKCANINE CANCER PANEL has been clinically proven effective on a wide variety of tumor types. When a suspicious mass is identified, or the dog presents with other indicators common with cancer, the cancer panel is used to detect the presence of neoplastic disease.

TKCANINE CANCER PANEL combines the information obtained from two independent measures of cellular irregularity; abnormal cell division and systemic inflammation. Thymidine kinase type 1 (TK1) is a measure of dysregulated cellular proliferation – a hallmark of cancer. C-reactive protein (CRP) is elevated in the presence of systemic inflammatory disease. United through the Neoplasia Index (NI), the test panel provides objective evaluation for disease.

The panel is useful for monitoring treatment and disease progression. For patients undergoing therapy, results from the cancer panel can quickly indicate that the patient is responding to the treatment protocol, as indicated when both TK1 and CRP decline from the initial pretreatment assessment. With resistance to therapy, TK1 and CRP will be unresponsive and remain elevated. Upon disease recurrence, TK1 and CRP will elevate from baseline. Retesting intervals are recommended at 4-8 week intervals.